FSD Pharma Inc (Nasdaq:HUGE) (CSE:HUGE.CN) (FRA:0K9A) said on Thursday that it has decided to forfeit the licences of its wholly-owned subsidiary FV Pharma Inc and suspend all activities of the business within 30 days.
Consequently, FSD Pharma has begun the process of liquidating all of FV Pharma's assets, including the sale of the company's cannabis production facility in Cobourg, Ontario.
Raza Bokhari, MD, executive co-chairman and CEO of FSD Pharma, said the company believes that shareholder value is best served by closing down the medicinal grade cannabis operation and focusing instead on advancing pharmaceutical R&D efforts for its lead compound FSD201 (ultra-micronised PEA) and continuing to explore the acquisition of other compounds to expand its drug development pipeline.
Bokhari added: "Our pharmaceutical R&D team led by Dr Edward Brennan is actively working to submit an Investigational New Drug Application (IND) to the FDA for the use of FSD201 to treat hospitalised COVID-19 patients by down-regulating the over-expressed pro-inflammatory cytokine immune response to SARS-CoV-2 virus infection. We are hopeful to initiate the phase 2 clinical trial before the end of this year and remain cautiously optimistic that our study may improve treatment outcome for COVID-19 patients."
NeoImmuneTech names new president and chief executive officer
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins